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fibrillation (VT/VF), post-operative stroke (CVA), and post-operative myocardial infarction
(MI).
Methods: We conducted a meta-analysis to assess the effect of peri-operative amio-
darone on the incidence of morbidity and mortality. MEDLINE, CINAHL, Cochrane Cen-
tral Register of Controlled Trials, and EMBASE databases were searched through 5/2003
with the terms atrial fibrillation, amiodarone and surgery. Inclusion criteria were random-
ized controlled double-blind study design and primary outcome designated as incidence
of AF/AFL. AF/AFL, VT/VF, CVA, MI, and mortality data were pooled using the DerSimo-
nian-Laird method with a random effects model. Trial heterogeneity was assessed via the
Woolf Q statistic, and publication bias was assessed with Kendall’s test on standardized
effect vs. variance.
Results: Eight randomized controlled double blind placebo trials with a total of 1,527
patients were included in our analysis of the incidence of AF/AFL and mortality. Of these,
six trials (1,184 patients) reported data on VT/VF, CVA, and MI. Heterogeneity and publi-
cation bias were not detected. Amiodarone significantly decreased the incidence of AF/
AFL [odds ratio 0.539, 95% CI (0.428, 0.678), P<0.0001], VT/VF [odds ratio 0.308, 95%
CI (0.164, 0.579), P=0.0003], and CVA [odds ratio 0.434, 95% CI (0.203, 0.929),
P=0.0315], when compared to placebo. Amiodarone did not significantly decrease the
incidence of MI [odds ratio 0.821, 95% CI (0.265, 2.543), P=0.732] and had no impact on
mortality [odds ratio 1.043, 95% CI (0.460, 2.370), P=0.919].
Conclusion: Amiodarone significantly reduced not only the incidence of AF/AFL, but also
of VT/VF and CVA. This study has important clinical implications and illustrates the need
for future prospective studies adequately powered to detect reductions in cardiovascular
morbidity and mortality.
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1172-67 Use of Administrative Databases May Lead to Incorrect 
Estimates of the Effects of Nonaspirin Nonsteroidal 
Anti-Inflammatory Drugs on MIyocardial Infarction Risk
Stephen E. Kimmel, Jesse A. Berlin, Jane Jaskowiak, Lori Kishel, Brian L. Strom, 
University of Pennsylvania School of Medicine, Philadelphia, PA
Background: Studies using administrative, prescription databases have generally shown
no effect of most nonselective non-aspirin nonsteroidal anti-inflammatory drugs (NAN-
SAIDs) on cardiovascular risk. We analyzed data from a study that specifically addressed
the biases inherent in using prescription databases to determine the effect of these
potential biases.
Methods: In our case-control study of NANSAIDs and first MI, we determined the odds
ratio for prescription (Rx) NANSAIDs versus non-users on MI risk as follows: (1) Replicat-
ing administrative database studies by: including over-the-counter (OTC) NANSAID
users as “non-users,” not excluding aspirin (ASA) users, and not adjusting for confound-
ers typically unavailable in administrative databases (smoking, family history, body mass
index, education, and physical activity). (2) Analysis #1 after removing OTC NANSAIDs
from the “non-user” category. (3) Analysis #2, adding adjustment for the confounders
listed above. (4) Analysis #3 plus excluding ASA users.
Results: OTC NANSAIDs accounted for 79% of all NANSAID use. ASA use was 28%.
Replication of administrative database analyses led to a null result (table). As we
removed each potential bias from our study, the OR moved further from 1.0 and indicated
a significant benefit of NANSAIDS in the fully adjusted analysis (#4).
Conclusion: The inability to measure OTC NANSAIDs, exclude ASA users, and adjust
for confounding may bias studies of prescription NANSAIDs and MI towards showing no
effect.
1172-68 Does Statin Therapy Reduce Contrast-Induced 
Nephropathy? An Analysis From a Large Regional 
Registry of Contemporary Percutaneous Interventions
Sanjaya Khanal, Nizar Attallah, Dean E. Smith, Eva Kline-Rogers, David Share, Michael 
J. O'Donnell, Mauro Moscucci, Henry Ford Hopsital, Detroit, MI, University of Michigan, 
Ann Arbor, MI
Background: Intravascular administration of contrast media can have nephrotoxic
effects particularly in patients with baseline renal insufficiency. Along with lowering serum
cholesterol, statins have pleiotropic effects in the vasculature. It is unclear whether statin
use has a protective effect against contrast-induced nephropathy (CN).
Methods: We evaluated 29,409 patients who had both baseline pre-procedure and peak
post-procedure serum creatinine measured at the time of their percutaneous coronary
intervention (PCI). Baseline demographics and creatinine profile before and after the pro-
cedure were compared between patients who received pre-procedure statins and those
who did not. CN was defined as increase in serum creatinine of >0.5 mg/dl.
Results: Baseline clinical characteristics were similar between the 2 groups (table).
When compared to patients who did not receive pre-procedure statins, patients on pre-
procedure statins had a lower incidence of CN (4.9 vs. 6.8, p<0.0001) and a trend
towards reducion of nephropathy requiring dialysis (0.4 vs. 0.6, p=0.07). After adjust-
ments for comorbidities, pre-procedure statin use was associated with a significant
reduction in CN (OR 0.81, 95% CI 0.72-0.92, p=0.0009).
Conclusions: Pre-procedure statin use is associated with significant reduction in CN
after contemporary PCI.
1172-69 Early Use of Small Molecule Platelet Glycoprotein IIb/IIIa 
Inhibitors for All Acute Coronary Syndrome Patients Is 
Superior to Selective Use of Abciximab for Only Those 
Requiring Percutaneous Coronary Interventions
Ruchira Glaser, Henry Glick, Howard C. Herrmann, Stephen E. Kimmel, University of 
Pennsylvania, Philadelphia, PA
Background: Selective use of medication may be important when several competing
therapies are available. Tirofiban and eptifibatide are small molecule platelet GP IIb/IIIa
inhibitors with benefit in acute coronary syndromes (ACS), but may not be as effective as
abciximab during percutaneous coronary intervention (PCI). However, abciximab does
not have proven efficacy in medical management of patients with ACS. No prior study
has attempted to balance the competing benefits of a strategy of giving all ACS patients a
small molecule versus a strategy of using abciximab only if a patient undergoes PCI. 
Methods: A decision analysis examined two treatment options and estimated under
what conditions one strategy was superior to another. The two strategies were (1) treat
all ACS patients initially with a small molecule GP IIb/IIIa inhibitor or (2) selectively use
abciximab only in ACS patients who ultimately undergo PCI. Sensitivity analyses were
performed over a wide range of assumptions. The primary outcome was life expectancy,
and cost effectiveness and bleeding were a secondary outcomes.
Results: The strategy of general use of a small molecule GP IIb/IIIa inhibitor on presen-
tation with ACS resulted in an average life expectancy of 15.93 years, compared with
15.71 years for selective use (life years savings of 0.22 years). The superiority of the gen-
eral use strategy persisted over all but extremes in sensitivity analyses. Preliminary cost
analyses showed general use as economically attractive, with cost per life year of less
than $50,000 over a wide range of assumptions. There was a similar likelihood of major
bleeding for patients with general use v. selective (6.5% v 6.1%).
Conclusion: General use of early GP IIb/IIIa inhibition in all patients presenting with
ACS leads to better outcomes than selective use. A selective use strategy may be supe-
rior only if a patient is extremely likely to undergo PCI (over 90%)or there is virtually no
reduction of events in medically managed patients receiving GP IIb/IIIa inhibition. When
faced with these competing strategies, the clinician should consider the significant, cost
effective benefits to general use of small molecule platelet GP IIb/IIIa inhibitors in ACS.
1172-70 Tolerability, Safety, and Efficacy of Beta-Blockade in 
Black Patients With Heart Failure in the Community 
Setting: Insights From a Large Prospective Beta-
Blocker Registry
William T. Abraham, Barry M. Massie, Mary Ann Lukas, Sandra R. Lottes, Jeanenne J. 
Nelson, Michael B. Fowler, Barry Greenberg, Edward M. Gilbert, Joseph A. Franciosa, 
and the COHERE Participant Physicians, GlaxoSmithKline Pharmaceuticals, 
Philadelphia, PA
Background: Conflicting data exist regarding the tolerability and efficacy of beta-block-
ade in Black patients with heart failure (HF). In randomized controlled trials bucindolol
appeared to worsen clinical outcome in Blacks while carvedilol apparently improved out-
come comparably to White patients.
Methods: The Coreg Heart Failure Registry (COHERE) prospectively evaluated the
early and 1-yr tolerability, safety, and efficacy of carvedilol in 4,280 HF patients treated in
the community setting.
Results: Prior to initiation of carvedilol, Black patients (n=523) differed from White
patients (n=3,433) in demonstrating more severe symptoms (NYHA Class III/IV, 44.3% vs
35.3%, p<0.001), more diabetes (37.1% vs 30.3%, p=0.002), less history of ischemic
Effects of Adjustment
Analysis
(see text)
Odds Ratio (95% CI)
#1 Replicating Administrative Database Analysis 1.0 (0.7-1.3)
#2 0.9 (0.7-1.1)
#3 0.8 (0.6-1.0)
#4 - Fully adjusted 0.7 (0.5-0.9)
Statin use and CN
Pre-statins No Pre-statins
Variable N=11,017 N=18,392 p-value
Age (mean (SD)), yrs 63.6 63.6 0.78
Female (%) 33.9 35.4 0.008
Baseline Creatinine (mean mg/dl) 1.2 1.2 0.50
Percent with Baseline Creatinine 1.5+mg/dl 12.9 12.6 0.54
Percent with Baseline Creatinine 2.0+mg/dl 4.8 5.0 0.42
Peak Creatinine (mean mg/dl) 1.3 1.3 0.30
Peak Creatinine 1.5+mg/dl 14.5 15.8 0.003
Peak Creatinine 2.0+mg/dl 6.6 7.9 <0.0001
Renal Failure Requiring Dialysis 0.4 0.6 0.07
Contrast Nephropathy 4.9 6.8 <0.0001
